New Adaptimmune management scores confidence boost with up to $897M+ Astellas deal
It makes sense to join forces with your partner’s owner.
Japan’s Astellas Pharma is tying up with UK-based Adaptimmune Therapeutics in a deal worth up to $897.5 million to develop stem-cell-derived, off-the-shelf T-cell therapies. Since 2015, Adaptimmune has been collaborating with a Seattle based company that makes customized stem cells — Universal Cells — which Astellas swallowed in 2018.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.